John LaMattina is a contributor to Forbes Magazine where is he one of the world’s thought-leaders in healthcare journalism. John was the president of Pfizer Global Research and Development from 2007 where he managed more than 13,000 scientists and professionals in the United States, Europe, and Asia for a decade. He is the author of "Drug Truths: Dispelling The Myths Of R&D" and the recently published “Devalued And Distrusted: Can The Pharmaceutical Industry Restore Its Broken Image?" John LaMattina is also a senior partner at PureTech Health, a leading biotech company investing in businesses that combat serious diseases. In this podcast, we discuss the potential impact on Bio-pharmaceutical innovation if the US Congress or Trump Administration succeed in passing their various international pricing proposals, which potentially have an impact of up to $70 billion of reduced revenue annually. As well, John LaMattina highlights the challenges of developing products for neurological disorders such as Alzheimer’s disease, and how the current R&D system is producing therapeutic breakthroughs in previously untreatable areas such as oncology and anti-infectives.See omnystudio.com/listener for privacy information.